Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
Completed
- Conditions
- Hypertension, Pulmonary
- Interventions
- Drug: Assigned pulmonary hypertension medication
- Registration Number
- NCT02576002
- Lead Sponsor
- Bayer
- Brief Summary
To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2691
Inclusion Criteria
- All PAH patients who were in the MarketScan database and who were under age 18 at some time during the years 2010 through 2013
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Pediatric PAH patients Assigned pulmonary hypertension medication US pediatric population with PAH in MarketScan database during the period 2010-2013
- Primary Outcome Measures
Name Time Method Incidence rate of PAH (pulmonary arterial hypertension) Retrospective analysis of three year period Prevalence rate of PAH Retrospective analysis of three year period
- Secondary Outcome Measures
Name Time Method Assigned drug treatment for PAH measured using the MarketScan database Retrospective analysis of three year period Description of pulmonary hypertension-targeted drugs prescribed in the study population and changes during the study period
Diagnostic procedures performed among PAH patients measured using the MarketScan database Retrospective analysis of three year period Prevalence of comorbidities among PAH patients Retrospective analysis of three year period
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pediatric PAH treatment with assigned pulmonary hypertension medications?
How does the assigned pulmonary hypertension medication compare to standard-of-care treatments in pediatric PAH patients?
Are there specific biomarkers that predict treatment response in pediatric pulmonary arterial hypertension?
What adverse events are associated with assigned pulmonary hypertension medications in children and how are they managed?
What are the current combination therapies or competitor drugs for treating pediatric pulmonary hypertension in the US?